Clinical trials: Lymphoma, Non-Hodgkin
Lymphoma
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00053027
- Testing
- rituximab, cladribine
- Volunteers
- 30 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma, B-Cell
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of relapsed or refractory B-cell Non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00998946
- Testing
- Pralatrexate, Vitamin B12, Folic Acid
- Where
- 11 sites in United States
- Volunteers
- 29 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
B-cell Lymphoma, Non-Hodgkin Lymphoma
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
- Conditions
- B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT05643742
- Testing
- CTX112
- Where
- 7 sites in United States, Australia
- Volunteers
- 120 people
- Sponsor
- CRISPR Therapeutics AG
Mycosis Fungoides
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
This study evaluates the effectiveness - as judged by complete response - of a single four-day treatment with the fusion protein A-dmDT390-bisFv(UCHT1) compared to oral Zolinza (Vorinostat), in a randomized 2-arm trial after a…
- Trial name
- Resimmune® (NCT02943642)
- Testing
- A-dmDT390-bisFv(UCHT1), Vorinostat
- Sponsor
- Virogen Biotechnology Inc.
Lymphoma
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients…
- Trial name
- NCT00052442
- Testing
- pralatrexate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.
- Conditions
- Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor, Cost-Benefit Analysis
- Trial name
- NCT04083079
- Testing
- PEG-rhG-CSF, rhG-CSF
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Ruijin Hospital
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
This phase II trial tests the safety, side effects and effectiveness of epcoritamab and tazemetostat in treating patients with grade I-IIIa follicular lymphoma that has come back after a period of improvement (relapsed) or that…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma
- Trial name
- NCT06575686
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Non-Hodgkin's Lymphoma
Treatment for Subjects With Non-Hodgkin's Lymphoma
This multicenter, open-label, randomized, parallel study was designed to evaluate whether a single fixed-dose subcutaneous (SC) administration of pegfilgrastim or daily administration of Filgrastim for absolute neutrophil count…
- Trial name
- NCT00117897
- Testing
- pegfilgrastim, Filgrastim
- Sponsor
- Amgen
Indolent Non-Hodgkin Lymphoma
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
This study examined the effects of predefined 2-week duvelisib dose holidays on tumor responses and safety/tolerability.
- Trial name
- TEMPO (NCT04038359)
- Testing
- Duvelisib
- Where
- 28 sites in United States, Czechia and 6 more
- Volunteers
- 103 people
- Sponsor
- SecuraBio
Peripheral T-Cell Lymphoma
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4.
- Trial name
- NCT01611142
- Testing
- KW-0761 (mogamulizumab)
- Where
- 15 sites in Denmark, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Non Hodgkin's Lymphoma
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
The purpose of this study is determine the optimal dose and schedule of Fusilev to prevent or reduce Mucositis in patients with Non-Hodgkin's Lymphoma receiving Folotyn treatment.
- Trial name
- NCT01789723
- Testing
- Fusilev, Folotyn
- Sponsor
- Acrotech Biopharma Inc.
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
Diffuse large B-cell lymphomas (DLBCL) are highly aggressive and heterogeneous B-cell lymphoma that would imminently be fatal without treatment.
- Trial name
- ExoReBLy (NCT03985696)
- Testing
- blood sample
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Lymphoma, B-Cell, Large B-cell Lymphoma
Relmacabtagene Autoleucel in Hematologic Malignancies
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
- Conditions
- Lymphoma, B-Cell, Large B-cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT06142188
- Testing
- Relmacabtagene Autoleucel
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
This is a phase II, open-label, multicentre study of Zanubrutinib-containing regimens in patients with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT06427213
- Testing
- Zanubrutinib,Obinutuzumab, Zanubrutinib and R-BAC
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
Diffuse, Large B-Cell, Lymphoma
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
The use of R-CHOP, given every two weeks, will be associated with improvements in response rate, and progression-free survival, when compared to R-CHOP given every three weeks.
- Trial name
- NCT00599170
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Southern California
Mantle Cell Lymphoma, Lymphoma, Mantle Cell
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
This study will evaluate the safety and effectiveness of an experimental cancer vaccine for mantle cell lymphoma a form of cancer of the white blood cells called lymphocytes.
- Trial name
- NCT00005780
- Testing
- EPOCH-R, GM-CSF, Idiotype vaccine
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment.
- Conditions
- CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01729806
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T-cell Lymphoma
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
This study is a Randomized Phase II Study to Compare Efficacy of CHOP versus Fractionated ICED in Transplant-eligible Patients with Previously Untreated Peripheral T-cell Lymphoma.
- Trial name
- NCT02445404
- Testing
- CHOP, fractionated ICED
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- Samsung Medical Center
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Trial name
- NCT01254578
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.